Comparatively, tirzepatide, the active ingredient in Zepbound and Mounjaro, demonstrated an average weight loss of 22.9% at 176 weeks with the 15 mg dose in the SURMOUNT-1 Phase 3 study in adults with pre-diabetes and obesity or overweight
Providers educate patients on how the medication affects appetite, recommend meal timing and portion strategies, and integrate behavioral interventions to reinforce healthier eating patterns
People taking diabetes medications, including metformin, sulfonylureas, or insulin, should be aware that adding chromium could potentially lower blood sugar further
This foundational dose allows your digestive system and appetite-control centers in the brain to adjust without overwhelming side effects
The process begins when the peptide enters the bloodstream and connects with MC1R
Read more about this recent study on our website